As an ERα target gene, LRIG1 is most highly expressed in ER-positive luminal disease relative to other breast cancer subtypes [14], with the lowest expression observed in basal/triple-negative breast cancers (TNBC) [19, 20]. Here, LRIG1 is linked to triple-negative breast carcinoma.